GPR109A — Drug Target

All drugs that target GPR109A — marketed and clinical-stage. Includes 2 drug classes acting on this target.

Drug classes

GPR109A agonist · lipid-regulating agent

Phase 3 pipeline (2)

• MK0524A, /Duration of Treatment : 4 Weeks · Merck Sharp & Dohme LLC · GPR109A agonist · Cardiovascular
  MK0524A is a niacin receptor agonist that activates GPR109A to raise HDL cholesterol and lower triglycerides.
• nicotine acid · GWT-TUD GmbH · lipid-regulating agent · Cardiovascular
  Nicotine acid, also known as niacin, primarily functions by reducing the production of very-low-density lipoprotein (VLDL) and low-density lipoprotein (LDL) cholesterol in the liver.